#immunotherapy — Monday, April 20, 2026 (2 items)
| 0 | ℹ |
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.
(nature.com)
|
Nature Medicine 2026-04-20 | #immunotherapy #car-t #toxicity #myeloma #minimal residual disease | |
| 0 | ℹ |
Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial.
(nature.com)
|
Nature Medicine 2026-04-20 | #immunotherapy #colitis #colorectal cancer #bispecific antibody #cytokine release syndrome |